| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
American Journal of Pathology, Vol 142, 319-328, Copyright © 1993 by American Society for Investigative Pathology
REGULAR ARTICLES |
RM Heuertz, CA Piquette and RO Webster
Cell and Molecular Biology Program, St. Louis University School of Medicine, Missouri.
In previous studies, we have shown that C-reactive protein (CRP) inhibits chemotaxis of neutrophils to complement fragments in vitro. To evaluate the effect of CRP on C5a-induced inflammation in vivo, a rabbit model of alveolitis was used. Rabbits pretreated with subcutaneous injections of croton oil had serum CRP increase from undetectable levels to 270 +/- 70 micrograms/ml 48 hours later. Rabbits were intubated and C5a des arg (10 micrograms/ml) instilled directly into the lungs via an endotracheal tube. Four to six hours later, the animals were killed and bronchoalveolar lavage performed. Rabbits pretreated with croton oil had significantly (P < 0.01) reduced C5a des arg-stimulated neutrophil infiltration (30 +/- 5%) into alveolar air spaces compared to untreated rabbits (64 +/- 9%). Increased numbers of total leukocytes in the alveolar washes coincided with increased neutrophil numbers whereas alveolar macrophages remained unchanged in all groups. Rabbits pretreated with croton oil also had a significant decrease (P < 0.05) in total protein (320 +/- 50 micrograms/ml) in lavage fluid after C5a instillation compared with untreated animals (850 +/- 140 micrograms/ml). In vitro, rabbit CRP (50 micrograms/ml) added to normal rabbit serum significantly (P < 0.05) inhibited chemotaxis of human neutrophils by 41%. Finally, direct intravenous pretreatment of rabbits with purified CRP also significantly reduced C5a-induced alveolitis. The CRP-C5a group had 33 +/- 10% neutrophil infiltration, a significant (P < 0.01) reduction from the C5a group (71 +/- 6%). The total protein content of the CRP-C5a rabbits was 986 +/- 165 micrograms/ml in the lavage fluid, which was significantly (P < 0.05) lower than the C5a group (1645 +/- 363 micrograms/ml). Therefore, CRP inhibits the development of neutrophil alveolitis and protein leakage in vivo and inhibits neutrophil chemotaxis in vitro. These data indicate that CRP offers a protective effect in neutrophil-mediated lung injury by reducing neutrophil influx and protein leak.
This article has been cited by other articles:
 |
|
 |
|
  E V Barnes, S Narain, A Naranjo, J Shuster, M S Segal, E S Sobel, A E Armstrong, B E Santiago, W H Reeves, and H B Richards High sensitivity C-reactive protein in systemic lupus erythematosus: relation to disease activity, clinical presentation and implications for cardiovascular risk Lupus, August 1, 2005; 14(8): 576 - 582. [Abstract] [PDF]
|
|
|
|
 |
|
 A. Steensberg, C. P. Fischer, C. Keller, K. Moller, and B. K. Pedersen IL-6 enhances plasma IL-1ra, IL-10, and cortisol in humans Am J Physiol Endocrinol Metab, August 1, 2003; 285(2): E433 - E437. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Mold, W. Rodriguez, B. Rodic-Polic, and T. W. Du Clos C-Reactive Protein Mediates Protection from Lipopolysaccharide Through Interactions With Fc{gamma}R J. Immunol., December 15, 2002; 169(12): 7019 - 7025. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. D. Barrett, J. K. Hennan, R. M. Marks, and B. R. Lucchesi C-Reactive-Protein-Associated Increase in Myocardial Infarct Size After Ischemia/Reperfusion J. Pharmacol. Exp. Ther., December 1, 2002; 303(3): 1007 - 1013. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. J. Szalai, S. Nataf, X.-Z. Hu, and S. R. Barnum Experimental Allergic Encephalomyelitis Is Inhibited in Transgenic Mice Expressing Human C-Reactive Protein J. Immunol., June 1, 2002; 168(11): 5792 - 5797. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Zouki, B. Haas, J. S. D. Chan, L. A. Potempa, and J. G. Filep Loss of Pentameric Symmetry of C-Reactive Protein Is Associated with Promotion of Neutrophil-Endothelial Cell Adhesion J. Immunol., November 1, 2001; 167(9): 5355 - 5361. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Balto, H. Sasaki, and P. Stashenko Interleukin-6 Deficiency Increases Inflammatory Bone Destruction Infect. Immun., February 1, 2001; 69(2): 744 - 750. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. K. Lagrand, C. A. Visser, W. T. Hermens, H. W. M. Niessen, F. W. A. Verheugt, G.-J. Wolbink, and C. E. Hack C-Reactive Protein as a Cardiovascular Risk Factor : More Than an Epiphenomenon? Circulation, July 6, 1999; 100(1): 96 - 102. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. M. Heuertz, S. M. Tricomi, U. R. Ezekiel, and R. O. Webster C-reactive Protein Inhibits Chemotactic Peptide-induced p38 Mitogen-activated Protein Kinase Activity and Human Neutrophil Movement J. Biol. Chem., June 18, 1999; 274(25): 17968 - 17974. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. A. Jones, D. Novick, S. Horiuchi, N. Yamamoto, A. J. Szalai, and G. M. Fuller C-reactive Protein: A Physiological Activator of Interleukin 6 Receptor Shedding J. Exp. Med., February 1, 1999; 189(3): 599 - 604. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Ayroldi, O. Zollo, L. Cannarile, F. D' Adamio, U. Grohmann, D. V. Delfino, and C. Riccardi Interleukin-6 (IL-6) Prevents Activation-Induced Cell Death: IL-2-Independent Inhibition of Fas/fasL Expression and Cell Death Blood, December 1, 1998; 92(11): 4212 - 4219. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. K. Lagrand, H. W.M. Niessen, G.-J. Wolbink, L. H. Jaspars, C. A. Visser, F. W.A. Verheugt, C. J.L.M. Meijer, and C. E. Hack C-Reactive Protein Colocalizes With Complement in Human Hearts During Acute Myocardial Infarction Circulation, January 7, 1997; 95(1): 97 - 103. [Abstract] [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
